company background image
CNTX

Context Therapeutics NasdaqCM:CNTX Stock Report

Last Price

US$1.12

Market Cap

US$17.9m

7D

-6.7%

1Y

n/a

Updated

03 Oct, 2022

Data

Company Financials +
CNTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CNTX Stock Overview

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States.

Context Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Context Therapeutics
Historical stock prices
Current Share PriceUS$1.12
52 Week HighUS$10.87
52 Week LowUS$1.06
Beta0
1 Month Change-40.43%
3 Month Change-44.00%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-78.04%

Recent News & Updates

Sep 27

Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24

Context Therapeutics (NASDAQ:CNTX) on Tuesday updated cash guidance to extend its runway into Q1 2024. The company plans to defer noncritical R&D activities, reduce future overhead and infrastructure expenditures, and prioritize its onapristone extended release (ONA-XR) ELONA Phase 1b/2 clinical trial and Claudin 6 (CLDN6) program. CNTX said it is evaluating ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients, who have previously been treated with a CDK4/6 inhibitor in Q4 this year and to report Phase 1b data in Q4 2023.

Sep 15
We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Aug 11

Context Therapeutics GAAP EPS of -$0.25 in-line

Context Therapeutics press release (NASDAQ:CNTX): Q2 GAAP EPS of -$0.25 in-line. Cash, cash equivalents, and restricted cash were $42.9 million.

Aug 02

Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial

Context Therapeutics (NASDAQ:CNTX) and Italian pharmaceutical major Menarini Group have entered into a clinical trial collaboration and supply agreement to evaluate a breast cancer combination treatment, the companies said on Tuesday. The agreement will support the upcoming phase 1b/2 ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor. Context (CNTX) will sponsor the trial while Menarini will supply elacestrant at no cost. CNTX said it anticipates starting the phase 1b/2 trial in Q4 this year. CNTX stock gained 5.8% to $2 in premarket trading.

May 28
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

CNTXUS PharmaceuticalsUS Market
7D-6.7%1.2%1.0%
1Yn/a4.4%-20.0%

Return vs Industry: Insufficient data to determine how CNTX performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CNTX performed against the US Market.

Price Volatility

Is CNTX's price volatile compared to industry and market?
CNTX volatility
CNTX Average Weekly Movement9.4%
Pharmaceuticals Industry Average Movement11.2%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: CNTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CNTX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20152Martin Lehrhttps://www.contexttherapeutics.com

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Context Therapeutics Inc. Fundamentals Summary

How do Context Therapeutics's earnings and revenue compare to its market cap?
CNTX fundamental statistics
Market CapUS$17.88m
Earnings (TTM)-US$11.96m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CNTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$11.96m
Earnings-US$11.96m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.75
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CNTX perform over the long term?

See historical performance and comparison